All In Biotech

Drug Trial Radar · NCT06553027

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Complications

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Sep 20, 2024

Primary completion

Aug 2026

Study completion Aug 2026

Sponsor

Lead sponsor
CerevanceIndustry
Sponsor type
Industry
First posted
Aug 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.

Conditions

  • Parkinson Disease

Interventions

  • CVN424 75 mgDrug

    Participants will receive 75 mg CVN424 tablet once daily.

  • CVN424 150 mgDrug

    Participants will receive 150 mg CVN424 tablet once daily.

  • PlaceboDrug

    Participants will receive matching placebo tablet once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 12 in average daily OFF time on motor diaries for 150 mg CVN424 compared to placeboTime frame: Baseline and Up to Week 12

Locations

94 sites in 9 countries. Site status is shown where the registry gives one.

  • The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham ALS Clinic

    Birmingham, Alabama

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Muhammad Ali Parkinson Center

    Phoenix, Arizona

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Parkinson's Research Centers of America - Orange county

    Aliso Viejo, California

  • Parkinson's Research Centers of America - Orange County

    Newport Beach, California

  • Parkinson's Research Centers of America - Palo Alto

    Palo Alto, California

  • CenExel Rocky Mountain Clinical Research

    Englewood, Colorado

  • David and Rhoda Chase Family Movement Disorders Center - Vernon

    Vernon, Connecticut

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida

  • SFM Clinical Research, LLC

    Boca Raton, Florida

  • K2 Medical Research

    Maitland, Florida

  • Renstar Medical Research

    Ocala, Florida

  • N1 Research LLc

    Orlando, Florida

  • Parkinson's Disease Center of SWFL

    Port Charlotte, Florida

  • University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - Brain & Spine Institute

    Port Orange, Florida

  • USF Parkinson's Disease and Movement Disorders Center

    Tampa, Florida

  • Atlanta Neuroscience Institute

    Atlanta, Georgia

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Kentucky, Dept of Neurology Kentucky Neuroscience Institute Research

    Lexington, Kentucky

  • Boston Clinical Trials

    Boston, Massachusetts

  • University of Michigan Dept. of Neurology

    Ann Arbor, Michigan

  • University of Michigan Hospital - Michigan Clinical Research Unit (MCRU)

    Ann Arbor, Michigan

  • Quest Research Institute

    Farmington Hills, Michigan

  • Boro Neurology

    Hopewell, New Jersey

  • Global Neurosciences Institute at Pennington

    Pennington, New Jersey

  • Parkinson's Research Centers of America - Long Island

    Commack, New York

  • Weill Cornell Medical College

    New York, New York

  • The Neurological Institute

    Charlotte, North Carolina

  • Duke Neurology Morreene Road Clinic

    Durham, North Carolina

  • Raleigh Neurology Associates

    Raleigh, North Carolina

  • Velocity Clinical Research

    Raleigh, North Carolina

  • Riverhills Healthcare, Inc dba Riverhills Neuroscience

    Cincinnati, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • The Ohio State University - Martha Morehouse Medical Plaza

    Columbus, Ohio

  • The Movement Disorder Clinic of Oklahoma

    Tulsa, Oklahoma

  • Oregon Health and Science University

    Portland, Oregon

  • Medical University of South Carolina

    Charleston, South Carolina

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.